Wat is de prijs voor Galmed Pharmaceuticals Ltd. (GLMD)

Het prijs van Galmed Pharmaceuticals Ltd. (GLMD) is $0.5225

Wat is de marktkapitalisatie voor Galmed Pharmaceuticals Ltd. (GLMD)

Marktkapitalisatie voorGalmed Pharmaceuticals Ltd. (GLMD) is $4.32M

Galmed Pharmaceuticals Ltd. (GLMD) Aandelensplitsingen

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land